计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Ravoxertinib 是可口服的ERK激酶抑制剂,抑制ERK1和ERK2的IC50分别为 6.1 和 3.1 nM。
体外活性
GDC-0994(p.o.)可抑制体内ERK磷酸化和ERK介导的信号转导通路的激活,随后阻碍ERK依赖性肿瘤细胞增殖和存活.在体外癌症模型中,GDC-0994(p.o.)可造成显著的多重单剂量活性,包括BRAF突变型和KRAS突变型人异种移植肿瘤的小鼠.
体内活性
GDC-0994对肿瘤细胞中的磷酸-p90RSK有显著抑制作用。
Information
Ravoxertinib (GDC-0994) Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
In vitro
GDC-0994 potently inhibits phospho-p90RSK in tumor cells.
In vivo
GDC-0994 (p.o.) results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. In vivo, GDC-0994 (p.o.) inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways, and subsequently prevents ERK-dependent tumor cell proliferation and survival.
Cell Data
cell lines:MM cells, including INA6, RPMI-8226, U266, and RPMI-Dox40
Concentrations:
Incubation Time:
Powder Purity:≥98%
| ALogP | 2 |
|---|